These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 22938185)

  • 1. Individualized, discrete event, simulations provide insight into inter- and intra-subject variability of extended-release, drug products.
    Kim SH; Jackson AJ; Hur R; Hunt CA
    Theor Biol Med Model; 2012 Aug; 9():39. PubMed ID: 22938185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico, experimental, mechanistic model for extended-release felodipine disposition exhibiting complex absorption and a highly variable food interaction.
    Kim SH; Jackson AJ; Hunt CA
    PLoS One; 2014; 9(9):e108392. PubMed ID: 25268237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proof of Concept in Assignment of Within-Subject Variability During Virtual Bioequivalence Studies: Propagation of Intra-Subject Variation in Gastrointestinal Physiology Using Physiologically Based Pharmacokinetic Modeling.
    Bego M; Patel N; Cristofoletti R; Rostami-Hodjegan A
    AAPS J; 2022 Jan; 24(1):21. PubMed ID: 34988679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically based absorption modeling to predict bioequivalence of controlled release and immediate release oral products.
    Mitra A; Petek B; Bajc A; Velagapudi R; Legen I
    Eur J Pharm Biopharm; 2019 Jan; 134():117-125. PubMed ID: 30472143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically Based Pharmacokinetic Modeling to Evaluate Formulation Factors Influencing Bioequivalence of Metoprolol Extended-Release Products.
    Basu S; Yang H; Fang L; Gonzalez-Sales M; Zhao L; Trame MN; Lesko L; Schmidt S
    J Clin Pharmacol; 2019 Sep; 59(9):1252-1263. PubMed ID: 31087553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation.
    Tsume Y; Amidon GL
    Mol Pharm; 2010 Aug; 7(4):1235-43. PubMed ID: 20557130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the Clinical Impact of Formulation Variability: A Metoprolol Extended-Release Case Study.
    Kim S; Sharma VD; Lingineni K; Farhan N; Fang L; Zhao L; Brown JD; Cristofoletti R; Vozmediano V; Ait-Oudhia S; Lesko LJ; Trame MN; Schmidt S
    J Clin Pharmacol; 2019 Sep; 59(9):1266-1274. PubMed ID: 31087554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
    Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioavailability and Bioequivalence Aspects of Oral Modified-Release Drug Products.
    Wang R; Conner DP; Li BV
    AAPS J; 2017 Mar; 19(2):360-366. PubMed ID: 28004346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vivo Predictive Dissolution (IPD) and Biopharmaceutical Modeling and Simulation: Future Use of Modern Approaches and Methodologies in a Regulatory Context.
    Lennernäs H; Lindahl A; Van Peer A; Ollier C; Flanagan T; Lionberger R; Nordmark A; Yamashita S; Yu L; Amidon GL; Fischer V; Sjögren E; Zane P; McAllister M; Abrahamsson B
    Mol Pharm; 2017 Apr; 14(4):1307-1314. PubMed ID: 28195732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment of a clinically relevant specification for dissolution testing using physiologically based pharmacokinetic (PBPK) modeling approaches.
    Kato T; Nakagawa H; Mikkaichi T; Miyano T; Matsumoto Y; Ando S
    Eur J Pharm Biopharm; 2020 Jun; 151():45-52. PubMed ID: 32298756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
    Kambayashi A; Blume H; Dressman J
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An alternative single dose parameter to avoid the need for steady-state studies on oral extended-release drug products.
    Paixão P; Gouveia LF; Morais JA
    Eur J Pharm Biopharm; 2012 Feb; 80(2):410-7. PubMed ID: 22108491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An investigation into the importance of "very rapid dissolution" criteria for drug bioequivalence demonstration using gastrointestinal simulation technology.
    Kovacevi I; Parojci J; Tubi-Grozdanis M; Langguth P
    AAPS J; 2009 Jun; 11(2):381-4. PubMed ID: 19455428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The bioequivalence of highly variable drugs and drug products.
    Midha KK; Rawson MJ; Hubbard JW
    Int J Clin Pharmacol Ther; 2005 Oct; 43(10):485-98. PubMed ID: 16240706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of Physiologically Based Absorption Modeling for Amphetamine Salts Drug Products in Generic Drug Evaluation.
    Babiskin AH; Zhang X
    J Pharm Sci; 2015 Sep; 104(9):3170-82. PubMed ID: 25973928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
    Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmaceutical Product Lead Optimization for Better In vivo Bioequivalence Performance: A case study of Diclofenac Sodium Extended Release Matrix Tablets.
    Shahiwala A; Zarar A
    Curr Drug Deliv; 2018; 15(5):705-715. PubMed ID: 29165078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variability and impact on design of bioequivalence studies.
    Van Peer A
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):146-53. PubMed ID: 20041877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.